Source - RNS
RNS Number : 5371T
Faron Pharmaceuticals Oy
13 October 2017
 

 

 

 

Faron Pharmaceuticals Oy

("Faron" or the "Company")

 

Notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities ("PDMR")

 

The notification below is being made in accordance with the requirements of the EU Market Abuse Regulation with reference to Dr Frank Armstrong's participation in the Placing and Subscription announced by the Company on 11 October 2017.

                                                                                                                                  

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Frank Armstrong                     

 

2

Reason for notification

 

 

 

a.

Position/Status

Person discharging managerial responsibilities

 

Non-executive Chairman

b.

Initial notification/

Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Faron Pharmaceuticals Oy

b.

LEI

7437009H31TO1DC0EB42

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares

ISIN: FI4000153309


b.

Nature of the transaction

Subscription

c.

Price(s) and volume(s)







Price(s)

Volume(s)


800 GBPp

1,250

 



 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

1,250

 

10,000 GBP

e.

Date of the transaction

11 October 2017

f.

Place of the transaction

Off-exchange transaction

 

 

For more information please contact:

 

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

[email protected]

 

Consilium Strategic Communications

Mary-Jane Elliott, Chris Welsh, Lindsey Neville

Phone: +44 (0)20 3709 5700

E-mail: [email protected]

 

Westwicke Partners, IR (US)

Chris Brinzey

Phone: 01 339 970 2843

E-Mail: [email protected]

 

Cairn Financial Advisers LLP, Nominated Adviser

Emma Earl, Tony Rawlinson

Phone: +44 207 213 0880

 

Panmure Gordon (UK) Limited, Joint Broker

Freddy Crossley, Duncan Monteith (Corporate Finance)

Tom Salvesen (Corporate Broking)

Phone: +44 207 886 2500

 

Whitman Howard Limited, Nominated Broker (UK)

Ranald McGregor-Smith, Francis North

Phone: +44 207 659 1234

 

About Faron Pharmaceuticals Ltd

 

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company's lead candidate Traumakine, to prevent vascular leakage and organ failures, is currently the only treatment for Acute Respiratory Distress Syndrome (ARDS) undergoing Phase III clinical trials.  There is currently no approved pharmaceutical treatment for ARDS. An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm ("RAAA"). Faron's second candidate Clevegen is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology ("TIET") may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at  www.faron.com

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHOKNDQOBDKFKD

Related Charts

Faron Pharmaceuticals (FARN)

0.00p (0.00%)
delayed 17:15PM